Diabetes and obesity therapeutics market will more than double to $163.2 billion by 2022
![](/46/pdcnewsitem/04/24/93/GBI%20Research.png)
A number of pipeline T2DM therapeutics are anticipated to be significant contributors to market growth over the forecast period, with some even expected to reach blockbuster status.
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to business intelligence firm GBI Research.
The company’s latest report states that although this growth is largely attributable to a large increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity, a number of pipeline T2DM therapeutics are anticipated to be significant contributors to market growth over the forecast period, with some even expected to reach blockbuster status.
Callum Dew, Associate Analyst for GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide). The disease cluster is dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.
“While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development. Of course, the growth of the disease cluster is driven not only by the rising global incidence of obesity, but also the subsequent effect that this has on T2DM incidence, given the intrinsic link between the two diseases.”
Invokana, which is marketed by Johnson & Johnson, is one of the key players in the disease cluster. It is expected to reach a huge $3.23 billion by 2022, and is set to be approved across T1DM, T2DM and obesity. Although current top-selling drugs such as Januvia, Novolog and Invokana are expected to remain dominant within the disease cluster, four of the anticipated top 10 best-selling drugs of 2022 will be new to market.
Dew concludes: “These products, which include dapagliflozin propanediol plus saxagliptin, NN-9535 and LixiLan, are expected to reach blockbuster status and become key players themselves, indicating the strength and diversity of both the market and the pipeline for diabetes.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance